NMS·Healthcare·$1.6B·#339 / 520 in Healthcare
VIR Vir Biotechnology, Inc.
34HIGH RISK
CATEGORY BREAKDOWN
GROWTH7
QUALITY60
STABILITY40
VALUATION5
GOVERNANCE35
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+4.4%
7
> 50% strong
Gross Margin
Revenue retained after direct costs
100.0%
100
> 50% strong
Cash Runway
Months of cash at current burn rate
7 months
16
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
12.8%
90
< 25% strong
Price / Sales
Market cap relative to trailing revenue
24.6x
5
< 3x strong
Rule of 40
Growth rate plus operating margin
-716
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
6.6%
48
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+21.4%
9
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE VIR WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when VIR's score changes by 5+ points.
DATA INFO
Last updated: Jul 1, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.